Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE‐HF trial. Issue 6 (26th March 2021)

• Record Type: Journal Article
• Authors: Nassif, Michael E.; Windsor, Sheryl L.; Tang, Fengming; Husain, Mansoor; Inzucchi, Silvio E.; McGuire, Darren K.; Pitt, Bertram; Scirica, Benjamin M.; Austin, Bethany; Fong, Michael W.; LaRue, Shane J.; Umpierrez, Guillermo; Hartupee, Justin; Khariton, Yevgeniy; Malik, Ali O.; Ogunniyi, Modele O.; Wenger, Nanette K.; Kosiborod, Mikhail N.
• Is Part Of: Diabetes, obesity & metabolism. Volume 23:Issue 6(2021)
• Page Start: 1426
• Page End: 1430
• Publication Date: 2021-03-26
• Subjects: dapagliflozin -- heart failure -- SGLT2 inhibitor; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.14352
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract: Sodium‐glucose cotransporter‐2 (SGLT2) inhibitors have been shown to reduce the risk of cardiovascular death or worsening heart failure (HF), and improve symptom burden, physical function and quality of life in patients with HF and reduced ejection fraction. The mechanisms of the HF benefits of SGLT2 inhibitors, however, remain unclear. In this substudy of the DEFINE‐HF trial, patients randomized to dapagliflozin or placebo had lung fluid volumes (LFVs) measured by remote dieletric sensing at baseline and after 12 weeks of therapy. A significantly greater proportion of dapagliflozin‐treated patients (as compared with placebo) experienced improvement in LFVs and fewer dapagliflozin‐treated patients had no change or deterioration in LFVs after 12 weeks of treatment. To our knowledge, this is the first study to suggest a direct effect of dapagliflozin (or any SGLT2 inhibitor) on more effective "decongestion", contributing in a meaningful way to the ongoing debate regarding the mechanisms of SGLT2 inhibitor HF benefits.